Patent: 10,189,797
✉ Email this page to a colleague
Summary for Patent: 10,189,797
| Title: | Chemical modulators of immune checkpoints and therapeutic use |
| Abstract: | Compounds and pharmaceutical compositions that down-regulate immune checkpoints such as PD-1, PD-L1 and CTLA-4 are provided. Also provided are methods of treating a disease by down-regulating immune checkpoints such as PD-1, PD-L1 and CTLA-4. The methods are useful for treating cancer and viral infection in a subject. |
| Inventor(s): | Chen; Wei (Chapel Hill, NC), Lyerly; Herbert Kim (Chapel Hill, NC), Ren; Xiu-rong (Durham, NC), Wang; Jiangbo (Durham, NC), Guo; Hongtao (Durham, NC), Hobeika; Amy (Durham, NC), Mook; Robert A. (Chapel Hill, NC) |
| Assignee: | Duke University (Durham, NC) |
| Application Number: | 15/395,464 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,189,797
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2035-12-30 |
| Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2035-12-30 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2035-12-30 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2035-12-30 |
| Amgen, Inc. | VECTIBIX | panitumumab | Injection | 125147 | 09/27/2006 | ⤷ Try a Trial | 2035-12-30 |
| Bristol-myers Squibb Company | YERVOY | ipilimumab | Injection | 125377 | 03/25/2011 | ⤷ Try a Trial | 2035-12-30 |
| Merck Sharp & Dohme Corp. | KEYTRUDA | pembrolizumab | For Injection | 125514 | 09/04/2014 | ⤷ Try a Trial | 2035-12-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
